Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sutro Biopharma (STRO) Equity Income (2020 - 2024)

Sutro Biopharma (STRO) has disclosed Equity Income for 5 consecutive years, with $4.8 million as the latest value for Q2 2024.

  • Quarterly Equity Income fell 42.22% to $4.8 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $4.8 million through Mar 2025, down 76.65% year-over-year, with the annual reading at $9.9 million for FY2023, 18.24% down from the prior year.
  • Equity Income hit $4.8 million in Q2 2024 for Sutro Biopharma, up from $3.7 million in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $48.9 million in Q2 2020 to a low of -$37.1 million in Q4 2020.
  • Historically, Equity Income has averaged $4.0 million across 5 years, with a median of $3.7 million in 2024.
  • Biggest five-year swings in Equity Income: skyrocketed 558.88% in 2022 and later crashed 1341.92% in 2023.
  • Year by year, Equity Income stood at -$37.1 million in 2020, then soared by 93.07% to -$2.6 million in 2021, then surged by 558.88% to $11.8 million in 2022, then crashed by 33.14% to $7.9 million in 2023, then plummeted by 39.09% to $4.8 million in 2024.
  • Business Quant data shows Equity Income for STRO at $4.8 million in Q2 2024, $3.7 million in Q1 2024, and $7.9 million in Q4 2023.